Artia Global Partners »

Ocular Therapeutix shares owned by Artia Global Partners

Quarter-by-quarter ownership of Ocular Therapeutix (OCUL) shares owned by Artia Global Partners from 13F filings

Historical chart of Artia Global Partners investment in Ocular Therapeutix

Tip: Access up to 7 years of quarterly data

All positions including Ocular Therapeutix held by Artia Global Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Ocular Therapeutix by Artia Global Partners

Quarter filed Position value Share count Share price at filing
2023-12-31 $2.0M 440k 4.46

More positions owned by Artia Global Partners

Novo-nordisk A S Adr (NVO)
Eli Lilly & Co. (LLY)
Merck & Co (MRK)
Cytokinetics Call Call Option
Cytokinetics Put Put Option
Eli Lilly & Co Put Put Option
Abbvie (ABBV)
Argenx Se Sponsored Adr (ARGX)
Astrazeneca Sponsored Adr (AZN)
Viking Therapeutics (VKTX)
Axsome Therapeutics (AXSM)
Neurocrine Biosciences (NBIX)
Intra Cellular Therapies (ITCI)
BioMarin Pharmaceutical (BMRN)
Cytokinetics Com New (CYTK)

View all positions for Artia Global Partners

Top funds holding Ocular Therapeutix

VR Adviser
Summer Road
Opaleye Management
Vanguard Group
Franklin Resources
Logos Global Management
Citadel Advisors
Deltec Asset Management
Millennium Management
Dr. Jeffrey R. Jay, M.D.
Banco Santander
Artia Global Partners
D. E. Shaw & Co
Essex Investment Management
Bank of New York Mellon

View all funds holding Ocular Therapeutix